Asia Pacific
Refine Search
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biosimilars
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the European Commission (EC) for their Opuviz 40mg/mL solution for injection in a vial, a biosimilar referencing Regeneron and Bayer’s Eylea (aflibercept). 18 November 2024
Biotechnology
Shanghai-based Junshi Biosciences has received UK regulatory approval for Loqtorzi (toripalimab) in nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). 18 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based clinical-stage biotech LaNova Medicines, bringing the US pharma giant into the newly attractive PD-1/VEGF bispecific antibody space. 15 November 2024
Biotechnology
Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the USA and Japan for advancing Atsena’s first- in-class, investigational gene therapy ATSN-101 for Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). 13 November 2024
Biotechnology
Anglo-American biotech Apollo Therapeutics and China-based Sunshine Lake Pharma have signed an exclusive license agreement to develop APL-18881, a bi-specific fusion protein aimed at treating metabolic diseases. 13 November 2024
Biotechnology
Dutch firm Argenx and China’s Zai Lab have received an approval from the National Medical Products Administration (NMPA) for Vyvgart Hytrulo (efgartigimod alfa). 13 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Biotechnology
Sino-American oncology company BeiGene has announced third-quarter 2024 financials, showing the total revenues was $1,002 million, up 28% compared to $781 million in the same period of 2023. 13 November 2024
Pharmaceutical
Li Li, Commissioner of China's National Medical Products Administration (NMPA), and Mette Aaboe Hansen, interim director general of Danish Medicines Agency, have signed a letter of intent to promote bilateral cooperation in regulation of drugs and medical devices. 11 November 2024
Pharmaceutical
India's pharma landscape has undergone a significant shift towards collaboration and partnership between global big pharma and domestic firms in recent years to drive innovation and expand market reach, according to GlobalData. 21 February 2024
Biotechnology
The Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy. 19 February 2024
Pharmaceutical
Japan’s Ono Pharmaceutical today announced that it has entered into a research collaboration agreement with USA-based artificial intelligence (AI) company to identify novel therapeutic targets by leveraging cutting-edge InveniAI’s AI and machine learning (ML). 19 February 2024
Pharmaceutical
Japanese drugmaker Kyowa Kirin announced that Phozevel Tablets (tenapanor hydrochloride, development code: KHK7791) will be launched in Japan on February 20 for the improvement of hyperphosphatemia in chronic kidney disease patients on dialysis. 19 February 2024
Pharmaceutical
Pharma giant Novartis has announced a strategic review of its listed entity in India. 19 February 2024
Biotechnology
Japanese drug major Astellas Pharma says its subsidiary Xyphos has entered into research and license agreement with privately-held Boston, USA-based Kelonia Therapeutics, to develop novel immuno-oncology therapeutics. 16 February 2024
Biotechnology
The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. 16 February 2024
Biotechnology
Japan’s Ono Pharmaceutical yesterday revealed that it has entered into an option and collaboration agreement with Swiss biotech Numab Therapeutics. 15 February 2024
Biotechnology
China-based biotech Brii Biosciences has entered into a second agreement with VBI Vaccines, sending the US firm’s up almost 10% to $0.72 in pre-market activity. 14 February 2024
Biotechnology
Japanese drugmaker Ono Pharmaceutical has entered into a drug discovery collaboration and option agreement with USA-based Shattuck Labs to generate bifunctional fusion proteins for pathways involved in autoimmune and inflammatory diseases. 13 February 2024
Pharmaceutical
Japanese pharma major Takeda has announced that the US Food and Drug Administration (FDA) has approved Eohilia (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE). 13 February 2024
Pharmaceutical
Shares of Japanese drugmaker Otsuka Pharmaceutical fell more than 5% to 5,359 yen today, as it released top line results of the Phase III clinical trial of AVP-786 in the treatment of agitation associated with dementia due to Alzheimer's disease. 13 February 2024
Biotechnology
Rare diseases specialist Swedish Orphan Biovitrum (also known as Sobi) has set up a joint venture with South Korean firm Handok to commercialize its drugs in the latter’s home market. 13 February 2024
Pharmaceutical
Japan’s largest drugmaker Takeda Pharma has announced positive top-line results from a randomized, double-blind, placebo-controlled, multiple dose Phase IIb trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients with narcolepsy type 1. 9 February 2024
Pharmaceutical
Vicor Pharma has entered into an exclusive licensing agreement with Japan’s Nippon Shinyaku, for the commercialization and development of its C21 idiopathic pulmonary fibrosis (IPF) drug candidate in Japan. 9 February 2024
Biotechnology
Crovalimab, a humanized complement inhibitor C5 monoclonal antibody discovered by Japan’s Chugai Pharmaceutical (TYO: 4519), has been approved by China’s National Medical Products Administration (NMPA) for treatment of PNH. 8 February 2024
Biotechnology
Immuno-oncology firm I-Mab saw its shares slip 4.5% to $1.91 pre-market today, as it announced that, as part of its strategy to become a USA-based biotech, it is divesting its Chinese subsidiaries. 8 February 2024
Biotechnology
China-based Hutchmed has reported data from FRUTIGA, its Phase III trial of fruquintinib alongside paclitaxel for the treatment of second-line advanced gastric cancer in China, at the American Society of Clinical Oncology (ASCO) Plenary Series Session. 8 February 2024
Biotechnology
Shares of French ophthalmology biotech Nicox shot up 16.8% to 0.48 euros this morning, after it announced a deal with privately-held Japanese firm Kowa Company. 8 February 2024
Biotechnology
Hong Kong-listed biotech BeiGene has received Health Canada authorization for Brukinsa (zanubrutinib) in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory grade 1, 2 or 3a follicular lymphoma (FL). 8 February 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze